Sunshine Biopharma Launches $4 Million At-The-Market Offering With Aegis Capital
Sunshine Biopharma entered into an At-The-Market Issuance Sales Agreement to raise up to $4.0 million by selling common stock through Aegis Capital as exclusive sales agent. Sales may be made from time to time on the Nasdaq Capital Market or other trading venues, with Aegis earning a 3.0% commissio…